Posted by Michael Wonder on 19 Jun 2025
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
16 June 2025 - With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Journey Program.
Eli Lilly today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499/month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program.
